NCT05933278View on ClinicalTrials.gov

Homologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine

PHASE2CompletedINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

July 25, 2023

Primary Completion Date

August 31, 2024

Study Completion Date

September 5, 2024

Conditions

COVID-19

Interventions

BIOLOGICAL

SARS-CoV-2 Subunit Recombinant Protein Vaccine

SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT Bio Farma

Trial Locations (1)

Unknown

Faculty of Medicine Diponegoro University, Semarang

Sponsors

Lead Sponsor

All Listed Sponsors

lead

PT Bio Farma

INDUSTRY